Quick Dispatch:
Your tirzepatide weight loss surmount-1 results percent weight loss 72 weeks Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide weight loss surmount-1 results percent weight loss 72 weeks Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ships.
Need Help?
Questions about tirzepatide weight loss surmount-1 results percent weight loss 72 weeks Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide weight loss surmount-1 results percent weight loss 72 weeks Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial in your area.
SURMOUNT-1 Trial
23.63
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency
23.08
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
28.30
I Was Right (and Wrong) About the Weight Management Space -
24.23
Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Horn - 2025 - Clinical Obesity
25.73
SURMOUNT-3: Tirzepatide shows total mean weight loss of 26.6% from study entry over 84 weeks
20.92
First head-to-head trial compares tirzepatide and semaglutide - Results are in!
25.66
